EL-22: The Engineered Probiotic Targeting the Muscle Loss That GLP-1 Drugs Leave Behind
BiohackingGLP-1 medications like semaglutide are extraordinarily effective at driving weight loss — but a meaningful portion of the weight they shed is lean muscle mass, not fat. A clinical-stage biotech has patented a potential solution that arrives via an unexpected mechanism: an engineered probiotic.
NorthStrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), recently filed U.S. Patent No. 19/655,160 for EL-22, described as a “myostatin-engineered probiotic.” The patent covers formulations and dosing regimens for a compound that combines Lactobacillus casei — a common probiotic strain — with modified myostatin antigens designed to reduce myostatin signaling in the body.
Context
Myostatin functions as a biological brake on muscle growth. It is produced by muscle cells and circulates in the bloodstream, suppressing the hypertrophic signaling that would otherwise drive muscle fiber development. Reducing myostatin activity — through genetic manipulation, antibody therapies, or in this case a modified antigen approach — is one of several mechanisms researchers have pursued to promote muscle preservation and growth.
The GLP-1 context is what makes this filing timely. Semaglutide and tirzepatide have driven substantial weight loss in large populations, but clinical evidence has consistently shown that a significant fraction of that weight loss comes from lean mass rather than adipose tissue. For patients using these medications as long-term metabolic management tools, the muscle loss has implications for metabolic rate, functional capacity, and longevity outcomes that extend well beyond the cosmetic framing of weight loss. The relationship between muscle mass and longevity is well-established: skeletal muscle mass and strength are among the strongest predictors of healthspan and all-cause mortality risk.
The Detail
EL-22’s mechanism is oral administration of a modified myostatin antigen delivered via a Lactobacillus casei vector. The hypothesis is that the antigen, presented through the gut immune system, triggers an immune response that reduces circulating myostatin levels — effectively downregulating the muscle growth inhibitor systemically, through a route that bypasses injectable delivery.
This approach, if validated, would represent a meaningful delivery innovation. Existing myostatin-targeting compounds under development are primarily injectable biologics — the same delivery barrier that limited early GLP-1 adoption before oral formulations matured. An orally administered probiotic that achieves systemic myostatin modulation would remove that barrier, though the mechanism also introduces questions about consistency, dose reproducibility, and immune response variation across individuals.
What NorthStrive does not have yet is clinical evidence. The current filing is a patent application covering formulations and dosing regimens — it precedes any published Phase 2 trial data. The company has described advancing toward Phase 2 trials, but the gap between a patent filing and frontline therapeutic use is substantial. Patent coverage and clinical validation are distinct milestones, and the latter is what the longevity and biohacking communities will need to see before EL-22 enters serious consideration as a protocol adjunct.
The So What
EL-22 is worth watching for two reasons, neither of which requires treating it as an imminent intervention. First, the mechanism is genuinely novel — if the probiotic vector approach achieves meaningful myostatin reduction, it opens a delivery pathway for muscle-targeting therapeutics that has not existed before. Second, the commercial framing around GLP-1 co-prescription is a structural thesis: as GLP-1 use continues to expand, the downstream market for muscle-preserving adjuncts grows with it.
For individuals currently using GLP-1 therapies, the established approaches to muscle preservation — resistance training volume, protein intake adequacy at around 1.6g/kg of body weight, and creatine supplementation — remain the evidence-based options. EL-22 is a compound to track as Phase 2 data emerges, not one to act on today.
Consult a qualified healthcare provider before modifying any treatment protocol.
Photo by Vladimir Srajber on Pexels
Source: Longevity Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →